Bio-Rad Laboratories Class A
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell BIO and other ETFs, options, and stocks.About BIO
Bio-Rad Laboratories, Inc. engages in the development, manufacturing, and marketing of a portfolio of instruments, systems, reagents, and consumables. It operates through the following segments: Life Science and Clinical Diagnostics.
BIO Key Statistics
Stock Snapshot
Bio-Rad Laboratories Class A(BIO) stock is priced at $287.34, giving the company a market capitalization of 7.71B. It carries a P/E multiple of 47.39.
During the trading session on 2026-05-21, Bio-Rad Laboratories Class A(BIO) shares reached a daily high of $290.56 and a low of $281.86. At a current price of $287.34, the stock is +1.9% higher than the low and still -1.1% under the high.
Trading activity shows a volume of 62.24K, compared to an average daily volume of 490.49K.
Over the past 52 weeks, Bio-Rad Laboratories Class A(BIO) stock has traded between a high of $343.12 and a low of $211.43.
Over the past 52 weeks, Bio-Rad Laboratories Class A(BIO) stock has traded between a high of $343.12 and a low of $211.43.
BIO News
Elliott Investment Management has built a significant stake in Bio-Rad Laboratories (NYSE:BIO). The activist position signals potential pressure for changes in...
Advertisement Recent performance snapshot Bio-Rad Laboratories (BIO) has drawn investor attention after a mixed run. The stock is up 13.9% over the past day a...
Bio-Rad develops instruments and software used by hospitals, blood banks, and medical laboratories. However, the company's founding family retains majority voti...
Analyst ratings
57%
of 7 ratingsMore BIO News
Bio-Rad (BIO) is up 11.6%, or $28.75 to $276.28. Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Discover top-perform...
Activist investor Elliott Investment Management has reportedly built a sizable stake in Bio-Rad Laboratories (BIO). According to the Wall Street Journal, Elliot...
Earlier this week, RBC Capital resumed coverage of Bio-Rad Laboratories, assigning an Outperform rating and emphasizing expectations for improved margins under...
Bio-Rad’s stock has dropped over 70% since trading at peak levels of over $800 a share in late 2021, during the Covid-19 pandemic. denis charlet / AFP / Getty I...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.